HLA-C and neoplasm: Following the upregulated expressions of various stimulatory molecules/receptors, the DCs migrate toward the draining lymph nodes to interact with the T cell and induce the immune response to finally present the tumor antigen derived from the vaccinated cells to the effector T cells (CD4 and CD8) via the formation of antigen–MHC complexes so that T cells can bind to these complexes present on the surface of the DCs with their receptors (TCRs) and become activated; this process leads to tumor killing [17].